ANCA-associated vasculitis (AAV) is an autoimmune disease that inflames small blood vessels, and the kidneys are its most frequent and most dangerous target. More than three-quarters of patients develop kidney involvement, typically in the form of rapidly progressive glomerulonephritis, a condition where the filtering units of the kidney deteriorate over weeks rather than years.1PubMed. ANCA-Associated Vasculitis: Core Curriculum 2020 Left untreated, that trajectory can end in kidney failure. With treatment, most patients achieve remission, but the disease demands long-term management, and the kidneys remain vulnerable at every stage.
What ANCA Vasculitis Does to the Kidneys
The name gives a clue. “ANCA” stands for anti-neutrophil cytoplasmic antibodies, which are autoantibodies that mistakenly target proteins on a type of white blood cell called neutrophils. When these antibodies latch onto neutrophils, they activate them in all the wrong places, particularly inside the tiny blood vessels of the kidneys. Activated neutrophils release reactive oxygen species and form web-like structures made of DNA and antimicrobial proteins, known as neutrophil extracellular traps. In healthy people these traps help fight infection, but in AAV patients the traps are produced in excess or cleared too slowly, triggering further autoantibody production and fueling a cycle of vascular damage.2PubMed Central. Neutrophil Extracellular Traps in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Diagnostic and Clinical Significance Neutrophils from AAV patients also tend to be more easily activated than those from healthy people, partly because of changes in the way genes for the target proteins are switched on and off.3PubMed Central. Neutrophil Extracellular Traps (NETs) and Vasculitis
The complement system, a branch of the immune system that normally helps clear infections, adds fuel to the fire. Patients with active AAV have significantly higher blood levels of the complement fragment C5a compared to patients in remission or healthy controls.4PubMed Central. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis C5a draws more neutrophils toward inflamed vessels and primes them for activation, amplifying the damage. This particular piece of the puzzle has become a therapeutic target, which is worth returning to later.
In the kidney, all of this plays out in the glomeruli, the tiny capillary tufts where blood is filtered. The hallmark finding on biopsy is “pauci-immune” glomerulonephritis, meaning inflammation with very little antibody or complement deposition visible under the microscope. Instead, you see crescent-shaped accumulations of cells inside the glomerular capsule, a sign that the filtering barrier has been breached and the body is responding chaotically. Without treatment, those crescents progress to scarring, and scarred glomeruli no longer filter blood.
MPO Versus PR3 and Why It Matters for the Kidneys
The two main ANCA targets are myeloperoxidase (MPO) and proteinase 3 (PR3), and the distinction is more than academic. The clinical syndromes overlap, but the kidney consequences differ in important ways. Patients with MPO-ANCA tend to have worse kidney outcomes. One study of over 200 patients found that kidney survival was significantly worse in the MPO-ANCA group, with roughly double the hazard of reaching kidney failure compared to the PR3-ANCA group.5PubMed Central. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis
Biopsy findings help explain the gap. MPO-ANCA patients show more glomerulosclerosis, which is permanent scarring of the filtering units. They also have more interstitial fibrosis, tubular atrophy, and other signs of chronic damage compared to PR3-ANCA patients.6PubMed. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups One interpretation is that MPO-ANCA disease may simmer at a low level for longer before diagnosis, allowing chronic damage to accumulate before anyone realizes what is going on. PR3-ANCA disease, by contrast, often declares itself more dramatically with systemic symptoms, which can paradoxically lead to earlier diagnosis and less entrenched kidney scarring.
Genome-wide studies have confirmed that these are genetically distinct conditions, not just variations of one disease. The strongest genetic signals track with the ANCA type, not the clinical diagnosis. PR3-ANCA is strongly linked to genes in the HLA-DP region and to the genes encoding proteinase 3 itself and its inhibitor, while MPO-ANCA maps to HLA-DQ and HLA-DR regions.7PubMed Central. Genetically distinct subsets within ANCA-associated vasculitis More recent work has pinpointed specific variants at the HLA-DPB1 locus that carry the largest single effect on AAV risk, with odds ratios around three.8PubMed Central. Identification of Functional and Expression Polymorphisms Associated With Risk For Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis Scandinavian cohort studies have replicated the HLA-DPB1 association for PR3-AAV and identified HLA-DRB1*04:04 for MPO-AAV.9PubMed Central. The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population None of this is something patients can act on today, but it reinforces the clinical reality that MPO and PR3 disease behave differently and may eventually warrant distinct treatment strategies.
How the Disease Is Diagnosed
The classic scenario is someone who shows up with blood and protein in their urine, a rising creatinine level, and vague systemic symptoms like fatigue, weight loss, or joint pain. The kidney function may be declining fast enough to prompt urgent investigation. A blood test for ANCA antibodies is usually the first step. In one study of patients with biopsy-proven pauci-immune glomerulonephritis, a positive ANCA at any level had a sensitivity above 97%, meaning the test catches almost everyone who has the disease.10PubMed. Diagnostic accuracy of ANCA serology in ANCA-associated vasculitis with renal involvement Specificity was more modest at around 71%, so a positive result at a low level does not guarantee the diagnosis. A higher ANCA titer improved the balance between sensitivity and specificity considerably.
The definitive diagnosis almost always requires a kidney biopsy. The biopsy not only confirms the characteristic pauci-immune crescentic glomerulonephritis but also provides critical information for predicting how the kidneys will do. A widely used classification system divides biopsy findings into four categories: focal, crescentic, mixed, and sclerotic, based on the proportions of normal, actively inflamed, and scarred glomeruli. This classification system has real prognostic power for predicting kidney outcomes at one and five years.11PubMed. Histopathologic classification of ANCA-associated glomerulonephritis A newer tool called the Renal Risk Score may be even better at predicting long-term outcomes, including who will eventually progress to kidney failure.12PubMed Central. The prognostic value of two histopathologic classification models of ANCA-associated glomerulonephritis Both approaches help clinicians make treatment decisions and set realistic expectations.
Getting the Disease Under Control
The first phase of treatment, called induction, aims to shut down the active inflammation before it causes irreversible kidney damage. For decades, the standard approach was cyclophosphamide plus high-dose steroids. That combination transformed AAV from a near-universally fatal disease into a manageable one, pushing five-year survival to about 78%.13PubMed. Complications of long-term therapy for ANCA-associated systemic vasculitis Cyclophosphamide works, but its side effects, including infection risk, bladder toxicity, and increased cancer rates over time, pushed researchers to look for alternatives.
Rituximab, which depletes the B cells that produce the offending antibodies, proved to be at least as effective as cyclophosphamide. In the landmark RAVE trial, about 64% of rituximab-treated patients reached complete remission compared with 53% on cyclophosphamide, meeting the bar for noninferiority, with similar adverse event rates.14PubMed Central. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis A European trial focused specifically on patients with kidney involvement confirmed the finding: sustained remission rates were comparable (76% vs. 82%), and the improvement in kidney filtration rate at 12 months was similar in both groups.15PubMed. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis A later pooled analysis of these trials reinforced that remission rates, improvements in kidney function, and relapse rates were equivalent regardless of ANCA type or whether the patient had a new diagnosis or relapsing disease.16PubMed Central. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement Rituximab has since become a standard induction option, particularly for patients who want to avoid cyclophosphamide’s cumulative toxicity.
Reducing the Steroid Burden
High-dose glucocorticoids are the part of AAV treatment that patients often dread most. The long list of side effects, including weight gain, bone loss, diabetes, and mood disturbance, accumulates quickly when steroids are used for months. Two large trials have now tested whether steroid doses can be safely cut back.
The PEXIVAS trial, which enrolled over 650 patients with severe AAV, found that a reduced-dose glucocorticoid regimen was noninferior to the standard dose for the combined outcome of death or kidney failure. Serious infections in the first year dropped by about a third in the reduced-dose arm.17PubMed. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis A Japanese trial (LoVAS) tested an even more aggressive steroid reduction paired with rituximab: remission rates at six months were virtually identical between reduced and high-dose groups (71% vs. 69%), but serious adverse events were cut roughly in half in the reduced-dose arm, from about 37% of patients down to 19%.18PubMed Central. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis Together, these results have shifted practice toward getting patients off high-dose steroids faster.
Avacopan and the Complement Pathway
Remember that C5a complement fragment driving neutrophils toward kidney blood vessels? Avacopan is an oral drug that blocks the C5a receptor, aiming to interrupt the inflammatory loop at its source rather than broadly suppressing the immune system. In an early phase 2 trial, patients who received avacopan without any prednisone still achieved clinical response rates comparable to those on standard steroid-based treatment.19PubMed Central. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
The pivotal phase 3 ADVOCATE trial then tested avacopan head-to-head against a prednisone taper in over 300 patients, all of whom also received either rituximab or cyclophosphamide. At 26 weeks, remission rates were similar (about 72% vs. 70%), meeting the threshold for noninferiority. But at 52 weeks, avacopan pulled ahead: roughly 66% of patients on avacopan maintained sustained remission compared to 55% on prednisone, a statistically significant difference.20PubMed. Avacopan for the Treatment of ANCA-Associated Vasculitis The drug also improved kidney function, a finding attributed to its targeted dampening of complement-driven inflammation in the glomeruli.21PubMed. Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis Avacopan has now been approved in multiple countries and represents the first genuinely targeted therapy for AAV, one that replaces steroids rather than just adding another immunosuppressant to the pile.
Keeping Remission Once You Have It
Getting the disease quiet is only half the battle. AAV relapses frequently, and each relapse risks further kidney damage. Maintenance therapy to prevent flares is standard, and the question has been which drug does it best. The MAINRITSAN trial compared rituximab infusions every six months against daily azathioprine (a traditional oral immunosuppressant). At 28 months, only about 5% of rituximab patients had experienced a major relapse compared to 29% on azathioprine.22PubMed. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis An international trial specifically enrolling patients with relapsing disease confirmed the finding, with rituximab cutting the hazard of relapse by nearly 60%.23PubMed Central. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease For kidney protection, minimizing relapses matters enormously because each episode of active glomerulonephritis leaves behind more scar tissue.
How long maintenance therapy should continue is an open question. Many clinicians treat for at least two years after remission, and some extend to four or five years for patients who have already relapsed. The decision involves weighing the risk of relapse (which can destroy kidney function) against the risks of prolonged immunosuppression (mainly infections). There is no universally agreed stopping point, and the right answer varies by patient.
Monitoring Between Visits
Even during remission, routine urine and blood tests serve as an early warning system. One of the simplest markers, the presence of blood in the urine visible only under a microscope, turns out to be remarkably informative. Persistent hematuria during remission was associated with roughly a fourfold increase in the risk of kidney relapse in one study, even after accounting for other factors. Proteinuria, by contrast, did not predict relapse.24PubMed Central. The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis The longer the hematuria persisted, the higher the risk climbed, with each additional month contributing incrementally.
ANCA levels themselves are also tracked, though their predictive value is debated. In patients with granulomatosis with polyangiitis (the PR3-predominant subtype), MPO-ANCA positivity at 12 months after diagnosis was independently associated with a roughly 3.5-fold increase in subsequent relapses, and the presence of microscopic hematuria at the same time point added additional risk.25Seminars in Arthritis and Rheumatism. ANCA status and renal parameters at month 12 post-diagnosis can help predict subsequent relapses in patients with granulomatosis with polyangiitis A rising ANCA titer alone is not always enough to trigger a change in treatment, but when combined with active urine sediment, it should raise the alarm.
What Happens When the Kidneys Fail
Despite treatment, some patients progress to end-stage kidney disease and need dialysis or a transplant. Kidney transplantation is feasible and generally successful in AAV patients, but it carries some unique considerations. A meta-analysis found that AAV patients undergoing transplantation had a significantly elevated relapse rate compared to the general transplant population.26PubMed Central. Outcomes of Renal Transplantation in ANCA-Associated Vasculitis: A Systematic Review and Meta-Analysis A recent single-center study put more specific numbers on the risk: AAV relapse occurred in about 7% of transplant recipients, and the cumulative incidence rose to 12% by ten years after transplant. When relapses did occur, they had a devastating effect on the transplanted kidney: 60% of patients who relapsed lost their graft, compared with 11% of those who stayed in remission.27Kidney International Reports. Clinical Research Outcomes After Kidney Transplantation in Antineutrophil Cytoplasmic Autoantibody–Associated Renal Vasculitis
Because of this, most transplant centers require that the disease be in stable remission for at least 6 to 12 months before listing a patient for transplant. Post-transplant immunosuppression provides some protection against AAV relapse, but it does not eliminate the risk. Continued monitoring with urinalysis and ANCA levels remains important even after a successful transplant.
Plasma Exchange and Its Shrinking Role
Plasma exchange, which physically removes circulating antibodies from the blood, was for years a go-to intervention for patients presenting with severe kidney involvement or lung hemorrhage. The idea was logical: strip out the pathogenic ANCAs and give the kidneys a break while immunosuppressive drugs take effect. Smaller trials supported the approach, but the large PEXIVAS trial, enrolling over 700 patients, found no clear benefit of adding plasma exchange to standard immunosuppressive treatment for the combined endpoint of death or end-stage kidney disease.28PubMed Central. Plasma Exchange in ANCA-Associated Vasculitis: A Narrative Review As a result, the role of plasma exchange has narrowed considerably. Some clinicians still consider it for patients with life-threatening lung hemorrhage or those already on dialysis at presentation, but it is no longer a default part of treatment for severe renal AAV.
The Long-Term Toll Beyond the Kidneys
Even patients who reach remission and maintain kidney function face lasting consequences. Mortality in AAV remains elevated compared to the general population, driven largely by infections, cardiovascular disease, and malignancy, complications tied both to the disease itself and to years of immunosuppressive treatment.29PubMed. Complications of long-term therapy for ANCA-associated systemic vasculitis Mortality is highest in the first year after diagnosis, likely because that is when treatment is most intensive and the disease most active, but it stays elevated in subsequent years as well.
Fatigue is perhaps the most underappreciated burden. Patients in remission report significantly worse physical health than the general population, and they are more than twice as likely to experience severe fatigue. The striking finding from one study is that fatigue strongly correlated with impaired physical health, but it did not correlate with disease activity or accumulated organ damage.30PubMed Central. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis This means that getting the vasculitis under control does not necessarily make you feel well. An exploratory study went further, finding that over half of AAV patients with inactive disease met diagnostic criteria for chronic fatigue syndrome, and about a third of those also met criteria for fibromyalgia.31PubMed Central. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia: PR3-versus MPO-ANCA-associated vasculitis, an exploratory cross-sectional study These symptoms are real, disabling, and often invisible to standard clinical monitoring that focuses on blood counts and kidney function. They represent a major gap between what remission means on paper and how remission feels in daily life.
Environmental and Genetic Risk Factors
Most patients receive their AAV diagnosis without any obvious cause, but a few environmental exposures have been linked to the disease. Silica dust, encountered in mining, sandblasting, and certain construction and farming activities, has been associated with an increased risk of developing AAV.32PubMed Central. The Association between Silica Exposure and Development of ANCA-Associated Vasculitis: Systematic Review and Meta-analysis Certain medications, including hydralazine and propylthiouracil, can trigger ANCA production and a drug-induced form of the disease that may resolve when the drug is stopped. Infections have also been proposed as triggers, though the evidence there is less concrete.
On the genetic side, as noted earlier, the strongest susceptibility signals cluster in the HLA region and differ by ANCA type. But no single gene variant is sufficient to cause the disease. AAV develops from some combination of genetic predisposition and environmental trigger, with the immune system landing in a self-perpetuating cycle of neutrophil activation and vascular damage. Understanding those genetic subtypes may eventually help personalize treatment, steering MPO-ANCA patients toward different monitoring schedules or treatment intensities than PR3-ANCA patients, but that level of precision medicine is still evolving.